First New Treatment Approved for Small Cell Lung Cancer in 20 Years

2018-08-20T13:57:24+00:00August 17th, 2018|Hot Topics, News|1 Comment

Friday, August 17, 2018 – Today the U.S. Food and Drug Administration approved Opdivo (nivolumab), an immunotherapy treatment, for patients with metastatic small cell lung cancer (SCLC) with progression after platinum-based chemotherapy and at least one other line of therapy. Accelerated approval was granted for this therapy due to positive results of a recent study, Phase 1/2 CheckMate -032 trial. This is not only the first immunotherapy treatment approved for SCLC, but also the first new treatment for SCLC in 20 years!

Click here for the full press release.

Learn more about immunotherapy treatment for lung cancer.

Questions about your treatment plan? Connect with a specialist by clicking here or calling 1-800-298-2436.

One Comment

  1. ear clinic September 4, 2018 at 11:31 am - Reply

    great post very well written. thanks for sharing it…

    hearing aids

Leave A Comment